Anixa Biosciences, Inc. (NASDAQ:ANIX - Free Report) - Analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Anixa Biosciences in a note issued to investors on Tuesday, March 25th. HC Wainwright analyst Y. Chen expects that the company will post earnings of ($0.10) per share for the quarter. HC Wainwright has a "Buy" rating and a $7.00 price objective on the stock. The consensus estimate for Anixa Biosciences' current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Anixa Biosciences' Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.40) EPS.
Other research analysts have also issued reports about the company. Maxim Group assumed coverage on Anixa Biosciences in a research report on Friday, March 21st. They set a "buy" rating and a $10.00 target price on the stock. D. Boral Capital reaffirmed a "buy" rating and set a $10.00 target price on shares of Anixa Biosciences in a research note on Wednesday.
View Our Latest Analysis on ANIX
Anixa Biosciences Price Performance
Shares of NASDAQ:ANIX traded down $0.11 during trading on Wednesday, reaching $2.97. 81,233 shares of the company were exchanged, compared to its average volume of 97,441. Anixa Biosciences has a 12-month low of $2.07 and a 12-month high of $4.20. The business's fifty day simple moving average is $2.97 and its 200-day simple moving average is $3.00. The firm has a market capitalization of $95.63 million, a PE ratio of -7.62 and a beta of 0.86.
Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10).
Institutional Trading of Anixa Biosciences
Several institutional investors have recently made changes to their positions in ANIX. Millennium Management LLC bought a new stake in shares of Anixa Biosciences during the fourth quarter worth $26,000. Virtu Financial LLC acquired a new position in Anixa Biosciences during the third quarter valued at approximately $34,000. Renaissance Technologies LLC raised its position in shares of Anixa Biosciences by 36.5% in the fourth quarter. Renaissance Technologies LLC now owns 14,573 shares of the company's stock valued at $34,000 after purchasing an additional 3,900 shares during the period. Prosperity Wealth Management Inc. bought a new stake in shares of Anixa Biosciences during the fourth quarter worth approximately $54,000. Finally, Jane Street Group LLC bought a new position in Anixa Biosciences during the 4th quarter worth $67,000. 29.13% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity at Anixa Biosciences
In related news, CEO Amit Kumar purchased 43,000 shares of the company's stock in a transaction on Wednesday, January 15th. The shares were bought at an average cost of $2.23 per share, for a total transaction of $95,890.00. Following the transaction, the chief executive officer now owns 559,925 shares of the company's stock, valued at $1,248,632.75. This represents a 8.32 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director Lewis H. Titterton, Jr. bought 10,000 shares of the business's stock in a transaction that occurred on Friday, January 17th. The shares were acquired at an average cost of $2.57 per share, with a total value of $25,700.00. Following the completion of the purchase, the director now owns 922,334 shares of the company's stock, valued at approximately $2,370,398.38. The trade was a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 75,289 shares of company stock worth $177,021. 25.30% of the stock is currently owned by company insiders.
About Anixa Biosciences
(
Get Free Report)
Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.
Featured Stories
Before you consider Anixa Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anixa Biosciences wasn't on the list.
While Anixa Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
